Last reviewed · How we verify
NCT04482023: WWCOVID-19
Emotional Support and Stress Management in Patients Diagnosed With COVID-19
trial testing Training video on anxiety, fear and loneliness in the COVID-19 environment. in COVID-19 in 150 participants. Status unknown.
30 April 2021
Quick facts
| Lead sponsor | Corporacion Parc Tauli |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 23 March 2021 |
| Primary completion | 30 April 2021 |
| Estimated completion | 30 April 2021 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Training video on anxiety, fear and loneliness in the COVID-19 environment.
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
Corporacion Parc Tauli — full company profile →
Who can join
18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the study is to identify the knowledge that CCSPT nurses have in relation to care aimed at addressing anxiety, fear or loneliness and the use they have made of it in the recent crisis. The design of the research/action will also enable the training of the participating professionals to improve nursing care in these areas in the future
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04482023
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Corporacion Parc Tauli trials
Trials by the same sponsor.
- NCT07331805 — Conservative Management in Primary Spontaneous Pneumothorax: a Multicenter Randomized Non-inferiority Study · NA · not yet recruiting
- NCT06873360 — Medical Device for Oxaliplatin-Induced Neuropathy in Gastrointestinal Cancer Patients · completed
- NCT06900335 — Functional Connectome in Prader-Willi Syndrome: Neuroimaging and AI to Assess Therapeutic Impact · completed
- NCT06511700 — Implementation of the Intravitreal Injection Administered by Nurses · enrolling by invitation
- NCT07298720 — Assessing Fluid-responsiveness Using Non-invasive Hybrid Diffuse Optics on Peripheral Muscle · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04482023 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Corporacion Parc Tauli
- Last refreshed: 24 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04482023.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing